Advertisement

Biomag 96 pp 1064-1066 | Cite as

Effects of Acute, Oral Administration of Phenobarbital (1.6 mg/kg) to Healthy Subjects

  • W. G. Sannita
  • J. D. Lewine
  • E. L. Maclin
  • W. W. OrrisonJr.
  • S. Robinson
Conference paper

Abstract

The effects of barbiturates on the background EEG signal depend on the administered dose, with increments of fast frequency (peculiarly in the ∼15.0–25.0 Hz range) or low frequency EEG activities following administration at small to moderate or at large doses respectively. The increment of fast frequency EEG activity is referred to as distinctive of barbiturates [1–3] and has been documented in healthy volunteers 30–120 min after single, oral doses Phenobarbital (PB) as low as of 50 to 100 mg [4, 5], in spite of low drug plasma concentrations (below 6.9 µg/ml) and with pharmacokinetics and brain dynamics that were consistent with available evidence of early CNS bioavailability [6]. The ∼15.0–25.0 Hz frequency interval appears to be a spectral parameter with peculiar sensitivity to PB, with substantial correlation between EEG effect and drug plasma concentration [4–5]. The power increase in this frequency segment occurs earlier and at lower doses on central electrodes, therefore allowing inference about possible generators

Keywords

Root Mean Square GABAB Receptor Midline Thalamus Root Mean Square Signal Transmembrane Resistance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fink, M EEG and human psychopharmacology. Ann. Rev. Pharmacol. 1969, 9: 241–258.CrossRefGoogle Scholar
  2. 2.
    Sato, H. Relationship between serum levels and fast EEG activities in rats by a single administration of Phenobarbital. Electroenceph. clin. Neurophysiol. 1980, 50: 509–514.CrossRefGoogle Scholar
  3. 3.
    Schwartz, J., Feldstein, S., Fink, M., Shapiro, D.M. and Itil, T.M. Evidence for a characteristic EEG frequency response to thiopental. Electroenceph. clin. Neurophysiol. 1971, 31: 149–153CrossRefGoogle Scholar
  4. 4.
    Sannita, W.G., Rapallino, M.V., Rodriguez, G. and Rosadini, G. EEG effects and plasma concentrations of Phenobarbital in volunteers. Neuropharmacology 1980, 19: 927–930CrossRefGoogle Scholar
  5. 5.
    Sannita, W.G., Balbi, A., Giacchino, F. and Rosadini, G. Quantitative EEG effects and plasma concentration of Phenobarbital, 50 mg and 100 mg single-dose oral administration to healthy volunteers: evidence of early CNS bioavailability. Neuropsychobiol. 1990, 205–212Google Scholar
  6. 6.
    Viswanathan, C.T., Booker, H.E. and Welling, P.G. Pharmacokinetics of Phenobarbital following single or repeated doses. J. clin. Pharmacol. 1979, 3: 382–389Google Scholar
  7. 8.
    MacDonald, R. Antiepileptic drug actions. Epilepsia 1989, 30: 19–28MathSciNetCrossRefGoogle Scholar
  8. 9.
    Miller, J.W. and Ferrendelli, J.A. Characterization of GABAergjc seizure regulation in the midline thalamus. Neuropharmacology 1990, 29: 649–655CrossRefGoogle Scholar
  9. 10.
    Cruuelli, V. and Leresche, N. A role for GABAg receptors in excitation and inhibition of thalamocortical cells. Trends Neurosci. 1991, 14: 16–21CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • W. G. Sannita
    • 2
    • 3
  • J. D. Lewine
    • 1
  • E. L. Maclin
  • W. W. OrrisonJr.
    • 1
  • S. Robinson
  1. 1.New Mexico Institute of Neuroimaging and Department of RadiologyUNM Medical SchoolAlbuquerqueUSA
  2. 2.Department of PsychiatryState University of New YorkStony BrookUSA
  3. 3.Center of Neuropsychoactive Drugs, DISM-NeurophysiopathologyUniversity of GenovaGenovaItaly

Personalised recommendations